Show simple item record

dc.contributor.authorFernández-Fernández C
dc.contributor.authorCallado LF
dc.contributor.authorGirón R
dc.contributor.authorSánchez E
dc.contributor.authorErdozain AM
dc.contributor.authorLópez-Moreno JA
dc.contributor.authorMorales P
dc.contributor.authorRodríguez de Fonseca F
dc.contributor.authorFernández-Ruiz J
dc.contributor.authorGoya P
dc.contributor.authorMeana JJ
dc.contributor.authorMartín MI
dc.contributor.authorJagerovic N
dc.date.accessioned2019-10-25T20:38:33Z
dc.date.available2019-10-25T20:38:33Z
dc.date.created2017-09-28 23:37
dc.date.issued2014-02-01
dc.identifieroai:doaj.org/article:d3d78ed79857441da8e2e123d0feb345
dc.identifier1177-8881
dc.identifierhttps://doaj.org/article/d3d78ed79857441da8e2e123d0feb345
dc.identifier.urihttp://hdl.handle.net/20.500.12424/1517454
dc.description.abstractCristina Fernández-Fernández,1 Luis F Callado,2 Rocío Girón,3 Eva Sánchez,3 Amaia M Erdozain,2 José Antonio López-Moreno,4 Paula Morales,1 Fernando Rodríguez de Fonseca,5 Javier Fernández-Ruiz,6 Pilar Goya,1 J Javier Meana,2 M Isabel Martín,3 Nadine Jagerovic1 1Instituto de Química Médica, CSIC, Madrid, 2Departamento de Farmacología, Universidad del Pais Vasco, UPV/EHU, CIBERSAM, Leioa, 3Departamento de Farmacología y Nutrición, Ciencias de la Salud, Universidad Rey Juan Carlos, Alcorcón, 4Departamento de Psicobiologia, Universidad Complutense de Madrid, Madrid, 5Laboratorio de Medicina Regenerativa, Hospital Carlos Haya, Fundación IMABIS, Málaga, 6Departamento de Bioquímica y Biología Molecular, Facultad de Medicina, CIBERNED, IRYCIS, Universidad Complutense de Madrid, Madrid, Spain Abstract: Based on numerous pharmacological studies that have revealed an interaction between cannabinoid and opioid systems at the molecular, neurochemical, and behavioral levels, a new series of hybrid molecules has been prepared by coupling the molecular features of two wellknown drugs, ie, rimonabant and fentanyl. The new compounds have been tested for their affinity and functionality regarding CB1 and CB2 cannabinoid and µ opioid receptors. In [35S]-GTPγS (guanosine 5’-O-[gamma-thio]triphosphate) binding assays from the post-mortem human frontal cortex, they proved to be CB1 cannabinoid antagonists and µ opioid antagonists. Interestingly, in vivo, the new compounds exhibited a significant dual antagonist action on the endocannabinoid and opioid systems. Keywords: fentanyl, rimonabant, cannabinoid, opioid, behavioral assays
dc.languageEN
dc.publisherDove Medical Press
dc.relation.ispartofhttp://www.dovepress.com/combining-rimonabant-and-fentanyl-in-a-single-entity-preparation-and-p-peer-reviewed-article-DDDT
dc.relation.ispartofhttps://doaj.org/toc/1177-8881
dc.sourceDrug Design, Development and Therapy, Vol 2014, Iss default, Pp 263-277 (2014)
dc.subjectMedicine
dc.subjectR
dc.subjectMedicine (General)
dc.subjectR5-920
dc.subjectTherapeutics. Pharmacology
dc.subjectRM1-950
dc.titleCombining rimonabant and fentanyl in a single entity: preparation and pharmacological results
dc.typeArticle
ge.collectioncodeOAIDATA
ge.dataimportlabelOAI metadata object
ge.identifier.legacyglobethics:11581776
ge.identifier.permalinkhttps://www.globethics.net/gel/11581776
ge.lastmodificationdate2017-09-28 23:37
ge.lastmodificationuseradmin@pointsoftware.ch (import)
ge.submissions0
ge.oai.exportid148650
ge.oai.repositoryid52
ge.oai.setnameLCC:Medicine
ge.oai.setnameLCC:Medicine (General)
ge.oai.setnameLCC:Therapeutics. Pharmacology
ge.oai.setspecTENDOk1lZGljaW5l
ge.oai.setspecTENDOk1lZGljaW5lIChHZW5lcmFsKQ~~
ge.oai.setspecTENDOlRoZXJhcGV1dGljcy4gUGhhcm1hY29sb2d5
ge.oai.streamid2
ge.setnameGlobeEthicsLib
ge.setspecglobeethicslib
ge.linkhttps://doaj.org/article/d3d78ed79857441da8e2e123d0feb345


This item appears in the following Collection(s)

Show simple item record